The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...
Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in ...
In 2023, Krystal Biotech received FDA approval for Vyjuvek as the first-ever revocable gene therapy for treating patients aged six months or older with DEB. In the fourth quarter of 2024, the company ...
Krystal, which won U.S. Food and Drug Administration approval of Vyjuvek in 2023, recorded $290.5 million in net product revenue for the drug last year. Write to Colin Kellaher at colin.kellaher@ ...
VYJUVEK was approved in the United States by the U.S. Food and Drug Agency (FDA) in May 2023 for the treatment of wounds in patients six months of age or older with DEB. The most common adverse ...
Nonetheless, shares surged post the quarterly release, mostly due to the strong uptake of Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first-ever revocable ...
Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback